This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
High-risk definition
High-risk MM per IMS-IMWG consensus
Patients must have 1 of the following:
- del(17p)* and/or TP53 mutation†
- One of the following translocations: t(4;14) or t(14;16) or t(14;20), which must co-occur with 1q+ and/or del(1p32)
- Monoallelic del(1p32) along with 1q+, or biallelic del(1p32)†
- High beta-2 microglobulin (> 5.5 mg/dL) with normal creatinine (< 1.2="" />
*CCF ≥20%, by analyses conducted on CD138-positive/purified cells. †Assessed using an NGS-based method.
1q+, gain (three copies) or amplification (≥4 copies) of the long arm of chromosome 1; CCF, cancer clonal fraction; IMS, International Myeloma Society; IMWG, International Myeloma Working Group; MM, multiple myeloma; NGS, next-generation sequencing.
Avet-Loiseau H, et al. J Clin Oncol. 2025;43(24):2739-2751.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.